PHARMAENGINE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93.3 TWD | 0.00% |
|
-0.53% | -11.56% |
| 05-02 | PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-24 | PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors | CI |
Evolution of the average Target Price on PharmaEngine, Inc.
Price target over the last 5 years
History of analyst recommendation changes
1a86b2f1bfc44caa133b492.Fk2UK69SPy7CBPUMTzSqB700aKQTkQsObjRGnTLPHIE.dzT9TpljeHazc4ZgCX3cafJQMZFq4EpZW3cp81qXScpiCrl0_wR9WYRGwQ~c93432c0272892870748e00059227d52
Analysts' Consensus
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
93.3
TWD
Average target price
106
TWD
Spread / Average Target
+13.61%
High Price Target
106
TWD
Spread / Highest target
+13.61%
Low Price Target
106
TWD
Spread / Lowest Target
+13.61%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- 4162 Stock
- Consensus PharmaEngine, Inc.
